Abstract

The present invention relates to sulphated compounds containing one to twelve monosaccharide subunits, for the treatment or prevention of anon-gastrointestinal disease or conditionby gastrointestinal absorption, wherein none of the monosaccharide subunits is pyranosyl with N-substitution at the 2-position relative to the anomeric carbon of the pyranosyl subunit. The present invention also relates to corresponding methods of treating or preventing anon-gastrointestinal disease or condition. Additionally, the present invention relates to a method of modifying, or testing for a modification in,the level of a cytokine in vivo, ex vivoor in vitro, said method comprising contacting a sulphated compound with a cell, wherein the compound comprises at least one monosaccharide subunit. The present invention also relates to unit dosage forms comprising at least 2.5g of any of the above compounds, to unit dosage forms comprising the molar equivalent of at least 1 g of any of the above compounds in theirfree acid and/or base form, and to unit dosage forms comprising any of the above compounds other than sucralfate.Preferred compounds of the present invention are sucrose octasulphate and sucralfate.

IPC Classes  ?

• A61K 31/7016 - Disaccharides, e.g. lactose, lactulose
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 37/00 - Drugs for immunological or allergic disorders

Abstract

The present invention is directed to methods of modifying, or testing for a modification in,the level of a cytokine in vivo, ex vivo or in vitro, said method comprising contacting a compound or a pharmaceuticallyacceptable salt thereof with a cell, said compound comprising at least one monosaccharide subunit comprising a glycosidic amine group. The present invention is also directed to a method of modifying, or testing for a modification in, the level of VEGF in vivo, ex vivo or in vitro, said method comprising contactinga compound with a cell, wherein the compound is PHA (phytohaemagglutinin), or a structurally similar protein.

IPC Classes  ?

• A61K 31/7008 - Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
• A61K 31/7016 - Disaccharides, e.g. lactose, lactulose
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 37/00 - Drugs for immunological or allergic disorders

Abstract

The present invention is directed to sulphated compounds comprising at least one glycosidic amine group, and polysaccharide, oligosaccharide, peptide and protein derivatives comprising such compounds, and mixtures thereof. The present invention is also directed to methods of synthesising such compounds. Such compounds may bind to a range of proteins, find application in methods of modifying, or testing for a modification in the level of a cytokine in vivo, ex vivo or in vitro, and find application in the treatment and/or prevention of inflammation, an inflammatory disorder, a proliferative disorder, an immune disorder, an angiogenesis-dependent disorder, a sensitivity disorder, an adverse endocrine reaction, a degenerative disorder, wound healing, depression, and other diseases and disorders.

IPC Classes  ?

• C07H 5/06 - Aminosugars
• C07H 5/08 - Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to sulfur, selenium, or tellurium
• A61K 31/7008 - Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine